Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Comments on 'Adaptive increase in sample size when interim results are promising: a practical guide with examples'.

Emerson SS, Levin GP, Emerson SC.

Stat Med. 2011 Dec 10;30(28):3285-301; discussion 3302-3. doi: 10.1002/sim.4271. No abstract available.

PMID:
22105691
2.

Comments on 'Adaptive increase in sample size when interim results are promising: a practical guide with examples' by C. R. Mehta and S. J. Pocock.

Glimm E.

Stat Med. 2012 Jan 13;31(1):98-9; author reply 99-100. doi: 10.1002/sim.4424. No abstract available.

PMID:
22213002
3.

Adaptive increase in sample size when interim results are promising: a practical guide with examples.

Mehta CR, Pocock SJ.

Stat Med. 2011 Dec 10;30(28):3267-84. doi: 10.1002/sim.4102. Epub 2010 Nov 30.

PMID:
22105690
4.

Plan to be flexible: a commentary on adaptive designs.

Shih WJ.

Biom J. 2006 Aug;48(4):656-9; discussion 660-2.

PMID:
16972718
5.
6.
7.

Small sample approach, and statistical and epidemiological aspects.

Offringa M, van der Lee H.

Handb Exp Pharmacol. 2011;205:181-202. doi: 10.1007/978-3-642-20195-0_9.

PMID:
21882112
8.

How practical are adaptive designs likely to be for confirmatory trials?

Gould AL.

Biom J. 2006 Aug;48(4):644-9; discussion 660-2.

PMID:
16972716
9.

Group-sequential methods for adaptive seamless phase II/III clinical trials.

Stallard N.

J Biopharm Stat. 2011 Jul;21(4):787-801. doi: 10.1080/10543406.2011.551335. Review.

PMID:
21516569
10.

Flexible design of two-stage adaptive procedures for phase III clinical trials.

Koyama T.

Contemp Clin Trials. 2007 Jul;28(4):500-13. Epub 2007 Jan 23.

PMID:
17307399
11.

A confirmatory seamless phase II/III clinical trial design incorporating short-term endpoint information.

Stallard N.

Stat Med. 2010 Apr 30;29(9):959-71. doi: 10.1002/sim.3863. Epub 2010 Feb 26.

PMID:
20191605
12.

Sample size estimation in phase III cancer clinical trials.

Curran D, Sylvester RJ, Hoctin Boes G.

Eur J Surg Oncol. 1999 Jun;25(3):244-50.

PMID:
10336801
13.

A seamless phase II/III design with sample-size re-estimation.

Bischoff W, Miller F.

J Biopharm Stat. 2009 Jul;19(4):595-609. doi: 10.1080/10543400902963193.

PMID:
20183428
14.

On group sequential designs comparing two binomial proportions.

Kepner JL.

J Biopharm Stat. 2010 Jan;20(1):145-59. doi: 10.1080/10543400903280621.

PMID:
20077254
15.

Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts.

Bretz F, Schmidli H, K├Ânig F, Racine A, Maurer W.

Biom J. 2006 Aug;48(4):623-34.

PMID:
16972714
16.

Targeting population entering phase III trials: a new stratified adaptive phase II design.

Tournoux-Facon C, De Rycke Y, Tubert-Bitter P.

Stat Med. 2011 Apr 15;30(8):801-11. doi: 10.1002/sim.4148. Epub 2011 Jan 12.

PMID:
21432875
17.

Confirmatory clinical trials with an adaptive design.

Koch A.

Biom J. 2006 Aug;48(4):574-85.

PMID:
16972708
19.

An urn model for odds-ratio-based response-adaptive phase III clinical trials for two or more treatments.

Basak GK, Biswas A, Volkov S.

J Biopharm Stat. 2009 Sep;19(5):838-56. doi: 10.1080/10543400903105331.

PMID:
20183447
20.

Supplemental Content

Support Center